Amgen Inc. (NASDAQ:AMGN) Amgen Meeting on Rare Disease February 22, 2024 4:00 PM ET Company Participants Justin Claeys - Vice President of Investor Relations Murdo Gordon - EVP, Global Commercial Operations Vikram Karnani - Executive, Rare Disease Business Paul Burton - Chief Medical Officer James Bradner - Chief Scientific Officer Conference Call Participants Jay Olson - Oppenheimer Michael Yee - Jefferies Yaron Werber - TD Cowen Conor Mackay - Capital Markets Robyn Karnauskas - Truist Securities Chris Sc ...

THOUSAND OAKS, Calif., Feb. 19, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will host a webcasted call at 1:00 p.m. PT on Thursday, February 22, 2024 to discuss Rare Disease, its newly added fourth pillar of growth, and provide insights on its rare disease strategy and opportunities, including marketed products and pipeline. Murdo Gordon, executive vice president of Global Commercial Operations at Amgen, Jay Bradner, executive vice president of Research and Development and chief scientific officer at Amgen, Vi ...

After facing difficulties last year following the rise in interest rates and a slowdown in merger activities, biotech companies are seeing a turnaround driven by attractive valuations and AI-led advances in medicine.The S&P Biotechnology Select Industry Index has gained 4.10% over the past year and 1.30% month to date.According to Financial Times, biotech firms are swiftly tapping into U.S. equity markets. Drug developers raised $6.2 billion in the markets in January, marking the highest amount raised since ...

Amgen Inc. Conference Call Summary Company Overview - **Company**: Amgen Inc. (NASDAQ: AMGN) - **Event**: Oppenheimer 34th Annual Healthcare Life Sciences Conference - **Date**: February 14, 2024 Key Industry and Company Insights Growth Potential and Therapeutic Areas - Amgen is optimistic about growth across four therapeutic areas: General Medicine, Oncology, Inflammation, and Rare Disease [3][4] - The company emphasizes a balanced portfolio, reducing dependency on any single area for growth [4] Obesity Program - MariTide - MariTide is highlighted as a lead program with a differentiated profile in obesity treatment [3] - Phase I data shows promising results, with a 14.5% weight loss after three monthly doses in a high-dose cohort [13] - Durability of weight loss is notable, with approximately 11% maintained after 150 days post-treatment [14] - A Phase II study with 592 patients is underway, focusing on various dosing regimens, with interim analysis expected mid-2024 [14][15] Product Performance and Sales Growth - In 2023, Amgen reported a 15% year-over-year volume growth and 9% product sales growth, driven by 18 products achieving record sales [5] - Specific products like Repatha and EVENITY showed significant growth, with Repatha at 37% and EVENITY at 44% year-over-year [6] Oncology Developments - BLINCYTO is expected to see growth due to positive Phase III data and updated NCCN guidelines [7] - Tarlatamab, a first-in-class medicine for small cell lung cancer, is set for a June PDUFA date, indicating strong potential for market entry [7][49] Inflammation Portfolio - Otezla continues to show growth potential, with a 6% increase in new patient starts in Q4 2023 [8][40] - TEZSPIRE recorded sales of $177 million in Q4 2023, with a total of $567 million for the year [8] Rare Disease Pipeline - Amgen is expanding its Rare Disease growth pillar, with more details to be shared in an upcoming investor event [9][51] Market Positioning and Commercial Strategy - The company plans to position MariTide with a focus on monthly or less frequent dosing, enhancing patient experience [31][36] - The potential market opportunity for MariTide is significant, targeting hundreds of millions of individuals with obesity [37] Competitive Landscape - Amgen is leveraging human genetic insights to inform drug design, particularly for obesity treatments [17][18] - The company is confident in MariTide's differentiated approach compared to existing therapies, focusing on efficacy, tolerability, and patient adherence [36][37] Future Outlook - Amgen's pipeline includes multiple first-in-class or best-in-class medicines across all therapeutic areas, with key data readouts anticipated in 2024 [9][10] - The company is committed to enhancing patient experience through innovative delivery methods and dosing strategies [31][32] Additional Important Points - The company is actively engaging with the medical community, leading to rapid enrollment in ongoing studies [22] - Amgen's manufacturing capabilities are positioned to support the commercial formulation of MariTide [31][32] - The upcoming rare disease event aims to provide insights into Amgen's newest therapeutic area [51]

Amgen Inc. (NASDAQ:AMGN) Oppenheimer 34th Annual Healthcare Life Sciences Conference February 14, 2024 12:00 PM ET Company Participants Justin Claeys - Vice President of Finance and Treasurer Murdo Gordon - Executive Vice President of Global Commercial Operations James Bradner - EVP of Research and Development and Chief Scientific Officer Justin Claeys - Vice President of Finance and Treasurer Conference Call Participants Jay Olson - Oppenheimer & Co Jay Olson Hello, everyone, and welcome to Oppenheimer’s 3 ...

It is entirely fair to state that weight loss treatments have massive transformational power. US FDA approval of weight loss medicines could help shrink millions of waistlines. All while boosting weight loss stocks, which we’ve already seen happen with Eli Lilly’s Zepbound, for example. The best part — there are even more weight loss stocks that could see a similar boost, including:Novo Nordisk (NVO)Source: joreks / Shutterstock.comNovo Nordisk (NYSE:NVO) produces Ozempic and Wegovy. Although the two drugs ...

Amgen (AMGN -1.34%) is well on its way to producing a medicine for obesity that could one day rival the blockbuster weight-loss drugs like Wegovy and Zepbound made by the segment's monarchs, Novo Nordisk (NVO -0.45%) and Eli Lilly (LLY 0.77%). If it succeeds, it'll be showing up to the market late, and it'll need to clear the high bar of proving that its product is worth using instead of the mainstays.Is its stock worth buying on what appears to be its long shot at accessing a market that's already white-ho ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-37702 Amgen Inc. (Exact name of registrant as specified in its charter) Delaware 95-3540776 (State or other jurisdiction of (I.R.S. Employer incorporation or organizat ...

Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Puma Biotech (PBYI) and Amgen (AMGN) . But which of these two stocks offers value investors a better bang for their buck right now? We'll need to take a closer look.There are plenty of strategies for discovering value stocks, but we have found that pairing a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system produces the best returns. The proven Zacks Rank puts an emph ...

Amgen (AMGN) reported fourth-quarter 2023 adjusted earnings of $4.71 per share, which beat the Zacks Consensus Estimate of $4.66. Earnings rose 15% year over year on higher revenues, which were partially offset by higher operating costs and higher interest expenses.Total revenues of $8.2 billion marginally beat the Zacks Consensus Estimate of $8.16 billion. Total revenues rose 20% year over year, driven by higher product sales.Total product revenues increased 20% from the year-ago quarter to $7.83 billion ( ...